Jennifer Patnaik
Concepts (416)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Visual Acuity | 27 | 2025 | 447 | 4.620 |
Why?
| | Cataract | 18 | 2024 | 223 | 3.930 |
Why?
| | Macular Degeneration | 16 | 2025 | 185 | 3.850 |
Why?
| | Geographic Atrophy | 12 | 2025 | 91 | 3.650 |
Why?
| | Phacoemulsification | 14 | 2025 | 120 | 2.630 |
Why?
| | Registries | 10 | 2025 | 2143 | 2.190 |
Why?
| | Wet Macular Degeneration | 7 | 2025 | 57 | 2.180 |
Why?
| | Diabetic Retinopathy | 13 | 2024 | 201 | 2.120 |
Why?
| | Lenses, Intraocular | 6 | 2022 | 45 | 1.880 |
Why?
| | Tomography, Optical Coherence | 11 | 2025 | 257 | 1.820 |
Why?
| | Fluorescein Angiography | 9 | 2025 | 175 | 1.700 |
Why?
| | Intraocular Pressure | 11 | 2025 | 315 | 1.600 |
Why?
| | Ophthalmology | 6 | 2025 | 105 | 1.490 |
Why?
| | Cataract Extraction | 10 | 2024 | 106 | 1.430 |
Why?
| | Glaucoma | 8 | 2025 | 241 | 1.180 |
Why?
| | Optometry | 2 | 2025 | 9 | 1.150 |
Why?
| | Optometrists | 2 | 2025 | 8 | 1.150 |
Why?
| | Keratomileusis, Laser In Situ | 3 | 2024 | 20 | 1.110 |
Why?
| | Follow-Up Studies | 23 | 2025 | 5194 | 1.010 |
Why?
| | Retinal Detachment | 6 | 2023 | 74 | 0.980 |
Why?
| | Photorefractive Keratectomy | 2 | 2024 | 20 | 0.960 |
Why?
| | Fovea Centralis | 1 | 2025 | 23 | 0.950 |
Why?
| | Acanthamoeba Keratitis | 1 | 2025 | 4 | 0.950 |
Why?
| | Eye Infections, Parasitic | 1 | 2025 | 6 | 0.940 |
Why?
| | Retinopathy of Prematurity | 3 | 2022 | 161 | 0.940 |
Why?
| | Myopia | 7 | 2024 | 55 | 0.930 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 10 | 0.930 |
Why?
| | Aged, 80 and over | 29 | 2025 | 7899 | 0.930 |
Why?
| | Retrospective Studies | 54 | 2026 | 16315 | 0.910 |
Why?
| | Burnout, Professional | 3 | 2025 | 458 | 0.820 |
Why?
| | Aged | 49 | 2025 | 24666 | 0.820 |
Why?
| | Refraction, Ocular | 6 | 2024 | 43 | 0.790 |
Why?
| | Humans | 119 | 2026 | 140898 | 0.790 |
Why?
| | Capsule Opacification | 2 | 2021 | 22 | 0.740 |
Why?
| | Intraoperative Complications | 6 | 2024 | 147 | 0.740 |
Why?
| | Eye Diseases | 2 | 2020 | 92 | 0.730 |
Why?
| | Presbyopia | 1 | 2022 | 15 | 0.720 |
Why?
| | Retinal Drusen | 4 | 2024 | 31 | 0.720 |
Why?
| | Uveitis | 4 | 2025 | 148 | 0.710 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.710 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.710 |
Why?
| | Trabeculectomy | 5 | 2025 | 74 | 0.700 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 23 | 0.700 |
Why?
| | Female | 73 | 2026 | 75540 | 0.690 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.690 |
Why?
| | Surveys and Questionnaires | 13 | 2025 | 5931 | 0.680 |
Why?
| | Automobile Driving | 2 | 2022 | 152 | 0.650 |
Why?
| | Dementia | 1 | 2023 | 262 | 0.630 |
Why?
| | Glaucoma, Open-Angle | 4 | 2023 | 104 | 0.630 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 28 | 0.630 |
Why?
| | Male | 66 | 2026 | 69893 | 0.620 |
Why?
| | Laser Therapy | 1 | 2021 | 128 | 0.620 |
Why?
| | Colorado | 21 | 2025 | 4597 | 0.620 |
Why?
| | Vitrectomy | 6 | 2025 | 78 | 0.590 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 142 | 0.580 |
Why?
| | Lens, Crystalline | 1 | 2020 | 133 | 0.580 |
Why?
| | Postoperative Complications | 6 | 2024 | 2813 | 0.570 |
Why?
| | Middle Aged | 37 | 2025 | 34487 | 0.570 |
Why?
| | Lasers, Excimer | 3 | 2024 | 29 | 0.550 |
Why?
| | Metformin | 1 | 2021 | 329 | 0.540 |
Why?
| | Strabismus | 3 | 2023 | 65 | 0.530 |
Why?
| | Complement Activation | 5 | 2025 | 415 | 0.520 |
Why?
| | West Nile Fever | 3 | 2011 | 53 | 0.520 |
Why?
| | Internal Medicine | 1 | 2019 | 273 | 0.500 |
Why?
| | Emergency Medicine | 1 | 2019 | 246 | 0.500 |
Why?
| | Refractive Errors | 3 | 2025 | 35 | 0.490 |
Why?
| | Complement System Proteins | 4 | 2025 | 332 | 0.480 |
Why?
| | Choroid | 3 | 2025 | 78 | 0.470 |
Why?
| | Prevalence | 7 | 2025 | 2780 | 0.470 |
Why?
| | Cross-Sectional Studies | 12 | 2025 | 5645 | 0.470 |
Why?
| | Family Practice | 1 | 2019 | 440 | 0.460 |
Why?
| | Self Report | 2 | 2022 | 858 | 0.450 |
Why?
| | Breast Neoplasms | 3 | 2011 | 2235 | 0.440 |
Why?
| | United States | 19 | 2026 | 15195 | 0.430 |
Why?
| | Lens Implantation, Intraocular | 5 | 2022 | 67 | 0.420 |
Why?
| | Cornea | 3 | 2025 | 154 | 0.420 |
Why?
| | Biomarkers | 9 | 2025 | 4175 | 0.420 |
Why?
| | Multimodal Imaging | 2 | 2025 | 119 | 0.410 |
Why?
| | Internet | 4 | 2023 | 682 | 0.410 |
Why?
| | Corneal Transplantation | 2 | 2025 | 17 | 0.400 |
Why?
| | Commerce | 2 | 2013 | 72 | 0.400 |
Why?
| | Diabetes Mellitus | 5 | 2024 | 1072 | 0.390 |
Why?
| | Vitreous Body | 4 | 2022 | 122 | 0.390 |
Why?
| | Fluocinolone Acetonide | 2 | 2023 | 15 | 0.380 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2024 | 550 | 0.380 |
Why?
| | Smoking Prevention | 1 | 2013 | 170 | 0.370 |
Why?
| | Risk Factors | 14 | 2025 | 10430 | 0.370 |
Why?
| | Tobacco Products | 1 | 2013 | 91 | 0.370 |
Why?
| | Ophthalmologic Surgical Procedures | 2 | 2025 | 84 | 0.370 |
Why?
| | Macula Lutea | 2 | 2023 | 22 | 0.360 |
Why?
| | Fundus Oculi | 3 | 2025 | 86 | 0.350 |
Why?
| | Retinal Diseases | 2 | 2023 | 96 | 0.340 |
Why?
| | Disease Notification | 2 | 2011 | 16 | 0.340 |
Why?
| | Lens Capsule, Crystalline | 2 | 2021 | 13 | 0.340 |
Why?
| | Angiogenesis Inhibitors | 2 | 2023 | 229 | 0.320 |
Why?
| | Artificial Intelligence | 2 | 2024 | 332 | 0.320 |
Why?
| | Complement Factor B | 2 | 2022 | 110 | 0.320 |
Why?
| | Comorbidity | 2 | 2011 | 1658 | 0.310 |
Why?
| | Tonometry, Ocular | 3 | 2025 | 103 | 0.300 |
Why?
| | Eye Injuries | 2 | 2021 | 53 | 0.300 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2023 | 2524 | 0.290 |
Why?
| | Treatment Outcome | 11 | 2025 | 11125 | 0.290 |
Why?
| | Laser Coagulation | 2 | 2025 | 71 | 0.270 |
Why?
| | Hepatitis A | 2 | 2011 | 26 | 0.270 |
Why?
| | Healthcare Disparities | 2 | 2025 | 671 | 0.270 |
Why?
| | Bangladesh | 3 | 2022 | 55 | 0.270 |
Why?
| | West Nile virus | 1 | 2007 | 42 | 0.270 |
Why?
| | Time Factors | 7 | 2025 | 6944 | 0.260 |
Why?
| | Health Promotion | 1 | 2013 | 748 | 0.260 |
Why?
| | Local Government | 1 | 2006 | 27 | 0.250 |
Why?
| | Restaurants | 1 | 2006 | 22 | 0.250 |
Why?
| | Adult | 23 | 2025 | 39134 | 0.250 |
Why?
| | Prospective Studies | 7 | 2025 | 7749 | 0.240 |
Why?
| | Vision Disorders | 3 | 2022 | 167 | 0.240 |
Why?
| | Keratoconjunctivitis | 1 | 2026 | 11 | 0.240 |
Why?
| | Chronic Disease | 2 | 2011 | 1811 | 0.240 |
Why?
| | Blepharitis | 1 | 2026 | 9 | 0.240 |
Why?
| | Mass Screening | 2 | 2024 | 1300 | 0.240 |
Why?
| | Public Health Administration | 1 | 2006 | 74 | 0.240 |
Why?
| | Scleritis | 2 | 2025 | 28 | 0.240 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 43 | 0.230 |
Why?
| | Infant | 11 | 2026 | 9790 | 0.230 |
Why?
| | Ciliary Body | 1 | 2025 | 40 | 0.230 |
Why?
| | Pilocarpine | 1 | 2025 | 16 | 0.230 |
Why?
| | Keratoconus | 1 | 2025 | 23 | 0.230 |
Why?
| | Pemphigoid, Benign Mucous Membrane | 1 | 2024 | 6 | 0.220 |
Why?
| | Glucocorticoids | 3 | 2024 | 533 | 0.220 |
Why?
| | Withholding Treatment | 1 | 2025 | 77 | 0.220 |
Why?
| | Surgery, Plastic | 1 | 2025 | 48 | 0.220 |
Why?
| | Quality of Life | 5 | 2023 | 3005 | 0.220 |
Why?
| | Occupational Stress | 1 | 2025 | 42 | 0.220 |
Why?
| | Education, Distance | 1 | 2025 | 54 | 0.220 |
Why?
| | Retinoblastoma | 1 | 2024 | 40 | 0.220 |
Why?
| | Birth Weight | 3 | 2022 | 511 | 0.220 |
Why?
| | Aberrometry | 2 | 2021 | 9 | 0.210 |
Why?
| | Gestational Age | 3 | 2022 | 952 | 0.210 |
Why?
| | Disease Progression | 4 | 2025 | 2791 | 0.210 |
Why?
| | Optics and Photonics | 2 | 2021 | 42 | 0.210 |
Why?
| | Telemedicine | 2 | 2024 | 886 | 0.210 |
Why?
| | Feasibility Studies | 2 | 2024 | 1022 | 0.200 |
Why?
| | Macular Edema | 1 | 2023 | 46 | 0.200 |
Why?
| | Postoperative Period | 5 | 2025 | 360 | 0.200 |
Why?
| | Job Satisfaction | 1 | 2025 | 224 | 0.200 |
Why?
| | Insulins | 1 | 2023 | 37 | 0.200 |
Why?
| | Homosexuality, Male | 2 | 2020 | 207 | 0.190 |
Why?
| | Eye Burns | 1 | 2022 | 14 | 0.190 |
Why?
| | Vision, Low | 1 | 2022 | 17 | 0.190 |
Why?
| | Young Adult | 6 | 2025 | 13646 | 0.190 |
Why?
| | Cohort Studies | 6 | 2022 | 5789 | 0.190 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 82 | 0.190 |
Why?
| | Endoscopy | 1 | 2025 | 323 | 0.190 |
Why?
| | Eyelid Diseases | 1 | 2022 | 23 | 0.190 |
Why?
| | Compartment Syndromes | 1 | 2022 | 31 | 0.190 |
Why?
| | Hospitals, Pediatric | 1 | 2026 | 532 | 0.180 |
Why?
| | Incidence | 5 | 2022 | 2782 | 0.180 |
Why?
| | Odds Ratio | 4 | 2019 | 1054 | 0.180 |
Why?
| | Eyeglasses | 1 | 2022 | 22 | 0.180 |
Why?
| | Corneal Ulcer | 1 | 2022 | 21 | 0.180 |
Why?
| | Retinal Perforations | 1 | 2022 | 19 | 0.180 |
Why?
| | Clothing | 1 | 2022 | 22 | 0.180 |
Why?
| | Child | 12 | 2026 | 22313 | 0.180 |
Why?
| | Ocular Hypertension | 1 | 2022 | 67 | 0.180 |
Why?
| | Patient Satisfaction | 2 | 2024 | 690 | 0.180 |
Why?
| | Adolescent | 10 | 2026 | 22027 | 0.170 |
Why?
| | Weapons | 1 | 2021 | 9 | 0.170 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.170 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.170 |
Why?
| | Neonatal Screening | 1 | 2022 | 172 | 0.170 |
Why?
| | Refractive Surgical Procedures | 1 | 2021 | 7 | 0.170 |
Why?
| | Eye Banks | 1 | 2020 | 6 | 0.170 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 58 | 0.170 |
Why?
| | Glaucoma Drainage Implants | 1 | 2021 | 45 | 0.170 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.170 |
Why?
| | Perception | 2 | 2021 | 375 | 0.170 |
Why?
| | Glycation End Products, Advanced | 1 | 2021 | 85 | 0.170 |
Why?
| | Accidents, Traffic | 1 | 2022 | 190 | 0.160 |
Why?
| | SEER Program | 2 | 2011 | 219 | 0.160 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 139 | 0.160 |
Why?
| | Scleral Buckling | 1 | 2019 | 18 | 0.160 |
Why?
| | Language | 1 | 2023 | 309 | 0.160 |
Why?
| | Retinal Hemorrhage | 1 | 2019 | 22 | 0.160 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2019 | 14 | 0.160 |
Why?
| | Hepatitis C | 1 | 2022 | 250 | 0.160 |
Why?
| | Health Status Disparities | 1 | 2023 | 297 | 0.160 |
Why?
| | Legislation, Drug | 1 | 2020 | 80 | 0.160 |
Why?
| | Protective Factors | 1 | 2019 | 96 | 0.150 |
Why?
| | Oculomotor Muscles | 1 | 2020 | 75 | 0.150 |
Why?
| | Head Injuries, Closed | 1 | 2019 | 49 | 0.150 |
Why?
| | Risk Assessment | 3 | 2019 | 3484 | 0.150 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 75 | 0.150 |
Why?
| | Specialization | 1 | 2020 | 130 | 0.150 |
Why?
| | Infant, Newborn | 5 | 2022 | 6257 | 0.150 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 38 | 0.150 |
Why?
| | Complement C3a | 1 | 2019 | 42 | 0.150 |
Why?
| | Accreditation | 1 | 2019 | 93 | 0.150 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.150 |
Why?
| | Cardiovascular Diseases | 1 | 2011 | 2082 | 0.150 |
Why?
| | Refugees | 1 | 2020 | 80 | 0.150 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 57 | 0.140 |
Why?
| | Patient Care | 1 | 2019 | 117 | 0.140 |
Why?
| | Down Syndrome | 1 | 2025 | 505 | 0.140 |
Why?
| | Case-Control Studies | 3 | 2022 | 3578 | 0.140 |
Why?
| | Medical Marijuana | 1 | 2020 | 124 | 0.140 |
Why?
| | Curriculum | 1 | 2025 | 1029 | 0.140 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 21 | 0.140 |
Why?
| | Infant, Premature | 1 | 2022 | 598 | 0.140 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 282 | 0.140 |
Why?
| | Trabecular Meshwork | 1 | 2018 | 79 | 0.140 |
Why?
| | Sexually Transmitted Diseases | 3 | 2004 | 165 | 0.130 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 223 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2025 | 1020 | 0.130 |
Why?
| | Child, Preschool | 8 | 2026 | 11462 | 0.130 |
Why?
| | Marijuana Smoking | 1 | 2020 | 262 | 0.130 |
Why?
| | Marijuana Use | 1 | 2020 | 220 | 0.120 |
Why?
| | Clinical Competence | 2 | 2025 | 1196 | 0.120 |
Why?
| | Logistic Models | 2 | 2019 | 2088 | 0.120 |
Why?
| | Recovery of Function | 1 | 2019 | 680 | 0.120 |
Why?
| | Disease Management | 1 | 2019 | 628 | 0.120 |
Why?
| | Population Surveillance | 2 | 2011 | 479 | 0.120 |
Why?
| | Inflammation | 3 | 2023 | 2891 | 0.110 |
Why?
| | Proportional Hazards Models | 2 | 2024 | 1261 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 523 | 0.110 |
Why?
| | Disease Outbreaks | 2 | 2008 | 418 | 0.100 |
Why?
| | Retinal Pigment Epithelium | 2 | 2024 | 77 | 0.100 |
Why?
| | Condoms | 2 | 2004 | 101 | 0.100 |
Why?
| | Physicians | 1 | 2022 | 928 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1104 | 0.100 |
Why?
| | Sexual Behavior | 4 | 2004 | 493 | 0.100 |
Why?
| | Melanoma | 1 | 2019 | 792 | 0.090 |
Why?
| | Medicare | 2 | 2024 | 806 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2019 | 853 | 0.090 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1368 | 0.090 |
Why?
| | Axial Length, Eye | 2 | 2024 | 16 | 0.090 |
Why?
| | Immunologic Factors | 2 | 2024 | 249 | 0.090 |
Why?
| | Diagnostic Errors | 1 | 2011 | 174 | 0.080 |
Why?
| | Shellfish Poisoning | 1 | 2009 | 1 | 0.080 |
Why?
| | Vibrio Infections | 1 | 2009 | 2 | 0.080 |
Why?
| | Shellfish | 1 | 2009 | 6 | 0.080 |
Why?
| | Primary Prevention | 1 | 2011 | 201 | 0.080 |
Why?
| | Food Industry | 1 | 2009 | 8 | 0.080 |
Why?
| | Sex Factors | 2 | 2025 | 2051 | 0.080 |
Why?
| | Food Microbiology | 1 | 2009 | 72 | 0.080 |
Why?
| | Cause of Death | 1 | 2011 | 441 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 907 | 0.070 |
Why?
| | Internship and Residency | 1 | 2019 | 1222 | 0.070 |
Why?
| | Mortality | 1 | 2011 | 359 | 0.070 |
Why?
| | Cryptosporidiosis | 1 | 2008 | 22 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2022 | 527 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2156 | 0.070 |
Why?
| | Anti-Inflammatory Agents | 2 | 2022 | 479 | 0.070 |
Why?
| | Disease Reservoirs | 1 | 2007 | 25 | 0.070 |
Why?
| | Maternal-Child Health Centers | 1 | 2007 | 9 | 0.070 |
Why?
| | Culicidae | 1 | 2007 | 35 | 0.070 |
Why?
| | Sentinel Surveillance | 1 | 2007 | 47 | 0.070 |
Why?
| | Health Services Administration | 1 | 2007 | 8 | 0.070 |
Why?
| | Gastroenteritis | 1 | 2008 | 68 | 0.070 |
Why?
| | Relief Work | 1 | 2007 | 19 | 0.070 |
Why?
| | Chickens | 1 | 2007 | 189 | 0.070 |
Why?
| | Telephone | 1 | 2008 | 180 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 851 | 0.070 |
Why?
| | Geography | 1 | 2007 | 199 | 0.060 |
Why?
| | Birds | 1 | 2007 | 100 | 0.060 |
Why?
| | Horses | 1 | 2007 | 200 | 0.060 |
Why?
| | Health Care Surveys | 1 | 2008 | 562 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3788 | 0.060 |
Why?
| | Disasters | 1 | 2007 | 99 | 0.060 |
Why?
| | Immunoglobulins | 1 | 2006 | 167 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2062 | 0.060 |
Why?
| | Smoking | 1 | 2013 | 1573 | 0.060 |
Why?
| | Environment | 1 | 2007 | 341 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1441 | 0.060 |
Why?
| | Corneal Topography | 1 | 2025 | 25 | 0.060 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.060 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 15 | 0.060 |
Why?
| | Azathioprine | 1 | 2025 | 51 | 0.060 |
Why?
| | Immunization Programs | 1 | 2007 | 221 | 0.060 |
Why?
| | Adalimumab | 1 | 2025 | 55 | 0.060 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 15 | 0.060 |
Why?
| | Tomography | 1 | 2025 | 45 | 0.060 |
Why?
| | Lubricant Eye Drops | 1 | 2024 | 9 | 0.060 |
Why?
| | Tertiary Care Centers | 1 | 2026 | 177 | 0.060 |
Why?
| | Ontario | 1 | 2024 | 95 | 0.060 |
Why?
| | Infliximab | 1 | 2025 | 111 | 0.060 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 118 | 0.050 |
Why?
| | Needs Assessment | 1 | 2007 | 384 | 0.050 |
Why?
| | Retinal Neoplasms | 1 | 2024 | 36 | 0.050 |
Why?
| | Conjunctivitis | 1 | 2024 | 31 | 0.050 |
Why?
| | Rwanda | 1 | 2024 | 32 | 0.050 |
Why?
| | Capacity Building | 1 | 2024 | 59 | 0.050 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 80 | 0.050 |
Why?
| | Patient Discharge | 1 | 2011 | 930 | 0.050 |
Why?
| | Vision Tests | 1 | 2023 | 19 | 0.050 |
Why?
| | Methotrexate | 1 | 2025 | 255 | 0.050 |
Why?
| | Attitude to Health | 1 | 2007 | 451 | 0.050 |
Why?
| | Hospitals, County | 1 | 2023 | 11 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 1048 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 117 | 0.050 |
Why?
| | Health Surveys | 2 | 2021 | 511 | 0.050 |
Why?
| | Postoperative Care | 1 | 2025 | 280 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2011 | 1125 | 0.050 |
Why?
| | Tobacco Use Disorder | 1 | 2005 | 237 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 215 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Gonorrhea | 1 | 2003 | 61 | 0.050 |
Why?
| | Mentors | 1 | 2024 | 212 | 0.050 |
Why?
| | Global Health | 1 | 2025 | 381 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 38 | 0.050 |
Why?
| | Orbit | 1 | 2022 | 70 | 0.050 |
Why?
| | Phenotype | 2 | 2022 | 3172 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2023 | 516 | 0.050 |
Why?
| | Drug Implants | 1 | 2022 | 82 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 150 | 0.050 |
Why?
| | Nicotine | 1 | 2005 | 339 | 0.050 |
Why?
| | Communication Barriers | 1 | 2023 | 115 | 0.050 |
Why?
| | Reference Standards | 1 | 2022 | 185 | 0.040 |
Why?
| | Capsulorhexis | 1 | 2021 | 8 | 0.040 |
Why?
| | Albumins | 1 | 2022 | 114 | 0.040 |
Why?
| | Safety-net Providers | 1 | 2023 | 124 | 0.040 |
Why?
| | Morbidity | 1 | 2022 | 320 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 180 | 0.040 |
Why?
| | Dissent and Disputes | 1 | 2021 | 19 | 0.040 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 117 | 0.040 |
Why?
| | Hepacivirus | 1 | 2022 | 238 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 68 | 0.040 |
Why?
| | Crowding | 1 | 2021 | 37 | 0.040 |
Why?
| | Smoking Cessation | 1 | 2005 | 431 | 0.040 |
Why?
| | Biometry | 1 | 2021 | 70 | 0.040 |
Why?
| | Myanmar | 1 | 2020 | 6 | 0.040 |
Why?
| | Myotomy | 1 | 2020 | 15 | 0.040 |
Why?
| | Risk-Taking | 1 | 2003 | 341 | 0.040 |
Why?
| | Vision, Binocular | 1 | 2020 | 41 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2020 | 60 | 0.040 |
Why?
| | Rupture | 1 | 2020 | 88 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2025 | 854 | 0.040 |
Why?
| | Eye Movements | 1 | 2020 | 87 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 501 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 1962 | 0.040 |
Why?
| | HIV | 1 | 2020 | 247 | 0.040 |
Why?
| | Health Education | 1 | 2003 | 360 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2021 | 453 | 0.040 |
Why?
| | Canada | 1 | 2020 | 419 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 416 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2019 | 40 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1815 | 0.040 |
Why?
| | Microscopy, Acoustic | 1 | 2018 | 9 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 257 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2018 | 38 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2019 | 122 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 143 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 1031 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 15 | 0.040 |
Why?
| | Pseudophakia | 1 | 2018 | 16 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 584 | 0.040 |
Why?
| | Circadian Rhythm | 1 | 2023 | 509 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 568 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 713 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2026 | 2898 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2020 | 338 | 0.030 |
Why?
| | Physical Examination | 1 | 2019 | 242 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 609 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2920 | 0.030 |
Why?
| | Ambulatory Care Facilities | 3 | 2004 | 246 | 0.030 |
Why?
| | Stents | 1 | 2021 | 531 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 794 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2024 | 949 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 525 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 785 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 753 | 0.030 |
Why?
| | Sleep | 1 | 2023 | 879 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3336 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1496 | 0.030 |
Why?
| | Program Evaluation | 2 | 2011 | 919 | 0.030 |
Why?
| | Anxiety | 1 | 2022 | 1076 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 1013 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1856 | 0.030 |
Why?
| | Child Abuse | 1 | 2019 | 545 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 1136 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 917 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 2003 | 0.020 |
Why?
| | Depression | 1 | 2022 | 1487 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1643 | 0.020 |
Why?
| | Animals | 3 | 2009 | 37579 | 0.020 |
Why?
| | Legionellosis | 1 | 2011 | 2 | 0.020 |
Why?
| | Blood Glucose | 1 | 2021 | 2273 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4060 | 0.020 |
Why?
| | Medical Audit | 1 | 2011 | 77 | 0.020 |
Why?
| | Whooping Cough | 1 | 2011 | 55 | 0.020 |
Why?
| | Haemophilus Infections | 1 | 2011 | 41 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2011 | 137 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1786 | 0.020 |
Why?
| | International Classification of Diseases | 1 | 2011 | 138 | 0.020 |
Why?
| | Cryptosporidium | 1 | 2008 | 14 | 0.020 |
Why?
| | Caliciviridae Infections | 1 | 2008 | 20 | 0.020 |
Why?
| | Norovirus | 1 | 2008 | 26 | 0.020 |
Why?
| | Aid to Families with Dependent Children | 1 | 2007 | 3 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2011 | 367 | 0.020 |
Why?
| | Faculty | 1 | 2008 | 153 | 0.020 |
Why?
| | Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2007 | 96 | 0.020 |
Why?
| | Family Characteristics | 1 | 2008 | 191 | 0.020 |
Why?
| | Medically Uninsured | 1 | 2007 | 136 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1968 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2007 | 168 | 0.010 |
Why?
| | Guideline Adherence | 1 | 2009 | 553 | 0.010 |
Why?
| | Maryland | 1 | 2005 | 60 | 0.010 |
Why?
| | Administration, Topical | 1 | 2005 | 149 | 0.010 |
Why?
| | Urban Health Services | 1 | 2004 | 68 | 0.010 |
Why?
| | Acute Disease | 1 | 2007 | 1010 | 0.010 |
Why?
| | Office Visits | 1 | 2003 | 95 | 0.010 |
Why?
| | Syphilis | 1 | 2003 | 34 | 0.010 |
Why?
| | Administration, Oral | 1 | 2005 | 802 | 0.010 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2003 | 278 | 0.010 |
Why?
| | Risk | 1 | 2004 | 903 | 0.010 |
Why?
| | Mothers | 1 | 2007 | 777 | 0.010 |
Why?
| | Urban Population | 1 | 2004 | 481 | 0.010 |
Why?
| | HIV Infections | 1 | 2003 | 2967 | 0.000 |
Why?
|
|
Patnaik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|